Abbott Laboratories (ABT) stock had a bullish inflow of $49 million worth of trades on uptick and an outflow of $38.9 million in downticks on Friday. The total uptick to downtick ratio stood at 1.26. The net money flow into the stock was $10.1 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $6.67 million. An inflow of $6.72 million block trade was recorded on downticks. $13.39 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 1.99 in favor of the bulls. However, Abbott Laboratories (ABT) stock traded down $0.21 , and reached $42.09, a drop of -0.5% over the previous day. On a weekly basis, the stock is -2.07%, over the previous weeks close.
The company Insiders own 0.26% of Abbott Laboratories shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 4.53% . Institutional Investors own 73.32% of Abbott Laboratories shares. During last six month period, the net percent change held by insiders has seen a change of 4.33%.
In a related news,The officer (Executive Vice President) of Abbott Laboratories, Fussell Stephen R sold 41,500 shares at $45.01 on July 28, 2016. The Insider selling transaction had a total value worth of $1,867,915. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Abbott Laboratories (NYSE:ABT): stock was range-bound between the intraday low of $41.89 and the intraday high of $42.45 after having opened at $42.36 on Fridays session. The stock finally closed in the red at $42.36, a loss of -0.50%. The stock remained in the red for the whole trading day. The total traded volume was 7,208,223 shares. The stock failed to cross $42.45 in Fridays trading. The stocks closing price on Thursday was $42.3.
Abbott Laboratories (ABT) : During the past 4 weeks, traders have been relatively bearish on Abbott Laboratories (ABT), hence the stock is down -6.88% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.56% relative to the S&P 500. The 4-week change in the price of the stock is -7% and the stock has fallen -2.07% in the past 1 week.
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.